In our continued efforts to elucidate the function of macrophage phenotype control in anti-cancer therapy, with emphasis on promoting the transition from M2 to M1 macrophages, analysis indicated that STING agonists promoted the local production of anti-angiogenic factors and normalized tumor-associated vasculature (96), suggesting that reprogramming macrophages into anti-tumor states was promising. This evidence concerns the gene STING1 and neoplasm.